Biotron Ltd., of Sydney, received a notice of allowance for U.S. Patent application 11/922,281, “Antiviral Compounds and Methods,” for the composition and methods of treatment with its antiviral compound BIT225. BIT225 is in a phase II trial in HCV genotype 3 patients.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter